Juva Life Successfully Scales Novel Compound JUVA-041 for Preclinical Studies and Eventual Commercialization, Highlighting Successful Chemistry Process
globenewswire.com
news
2022-10-17 00:00:00

VANCOUVER, British Columbia, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) ('Juva Life,' 'Juva,' or the 'Company'), a life science company with both pharmaceutical research and development and consumer-facing operations in cannabis production and distribution, today announced the successful scale up of promising proprietary molecule, JUVA-041, from microgram quantity to 5 gram quantity. The Company's approach through its proprietary platform is proving to be successful, showcasing superior medicinal chemistry, and a large commercial advantage.
